XTalks

NOVEMBER 19, 2021

This is a part of the precision cardiology approach and could lead to their use as prognostic indicators. James Januzzi, MD, staff cardiologist at Massachusetts General Hospital and Hutter Family professor of medicine at Harvard Medical School, specializes in biomarker testing in heart disease and treatment of heart failure.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

The Pharma Data

FEBRUARY 24, 2022

An efficient intervention assessed by UACR reduction may provide long-term benefits for patients,” said Rajiv Agarwal, MD, Professor of Medicine, Indiana University School of Medicine and VA Medical Centre, Indianapolis, USA and Chair of the study’s Steering Committee. “If

Clinical Development 52

Clinical Development Development Cardiology Life Science 52

The Pharma Data

SEPTEMBER 29, 2021

Heerspink, Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University center Groningen, Netherlands, and Co-Chair of the study’s Executive Committee.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

XTalks

JANUARY 19, 2024

Radiobiological and Clinical Considerations from CRO and Emerging Biotech Radiopharmaceuticals are medicinal formulations containing radioisotopes that are used in the field of nuclear medicine primarily for the diagnosis and treatment of various diseases, particularly cancer. There have been more than $1.7

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

JANUARY 20, 2021

Statistician: Dr. George Wells – Professor, School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa and Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute. Dr. Bennett is a board-certified cardiologist and board-eligible in critical care medicine.

Trials 52

Trials Cardiology Containment Development 52

The Pharma Data

NOVEMBER 8, 2021

In the FIGARO-DKD study, presented at ESC Congress 2021 and published in the New England Journal of Medicine, the prevalence of the first secondary endpoint, a compound of time to order failure, a sustained drop of estimated glomerular filtration rate (eGFR) ? cases in the finerenone arm and 395 (10.8)

Clinical Trials 52

Clinical Trials Clinical Trials Trials HR 52

The Pharma Data

MARCH 13, 2022

(NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. The root cause of many immunological diseases is immuno-inflammation, which requires specifically designed agents. .:

Dermatology 52

Dermatology Cardiology Development Medicine 52

The Pharma Data

JULY 12, 2021

Bakris, MD, Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, USA and principal investigator of the FIDELIO-DKD trial. The clinical data from FIGARO-DKD are scheduled for presentation at the European Society of Cardiology (ESC) Congress 2021 on August 28th.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

The Pharma Data

OCTOBER 28, 2021

Finerenone FIGARO-DKD study data: The results of Bayer’s Phase III study FIGARO-DKD, which evaluated finerenone in addition to standard of care in a broad patient population with CKD and T2D for CV outcomes, were presented at ESC Congress in August 2021 and simultaneously published in the New England Journal of Medicine.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52

The Pharma Data

SEPTEMBER 11, 2021

Results from EMPEROR-Preserved were presented at the European Society of Cardiology Congress 2021 on August 27 and published in The New England Journal of Medicine. No currently approved treatments have been clinically proven to significantly improve outcomes specifically for people with HFpEF. are on a low salt diet.

Medicine 52

Medicine Insulin FDA Approval Trials 52

The Pharma Data

NOVEMBER 5, 2021

EMPEROR Program clinical investigator and Emeritus Professor of Rectifiers and Cardiology at the University of Lorraine, France.”The vice chairman, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals,Inc.”The

Trials 52

Trials Cardiology Drugs Development 52

The Pharma Data

JULY 8, 2021

“We look forward to presenting the EMPEROR-Preserved results at ESC 2021, which should offer a significant breakthrough in cardiovascular medicine and a new hope for people with HFpEF, which is an increasingly prevalent public health issue. vice president, Product Development, Lilly. Wh a t is JARDIANCE?

Trials 52

Trials Doctor Doctors Medicine 52

The Pharma Data

AUGUST 30, 2021

The findings from the FIGARO-DKD study were presented today during a Hot Line session at ESC Congress 2021, and simultaneously published in the New England Journal of Medicine. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development.

HR 52

HR Cardiology Clinical Trials Clinical Trials 52

XTalks

SEPTEMBER 11, 2024

“Failure to study medications and other interventions in a broad sampling has led to women experiencing adverse effects from medications at nearly twice the rate of men ,” says Dr. Jaclyn Jansen, MD, MS, Medical Director of the Medical Department, General Medicine, Medpace. Precision medicine benefits breast cancer treatment.

Clinical Trials 103

Clinical Trials Clinical Trials Trials Hormones 103

The Pharma Data

MARCH 23, 2022

Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. Under his leadership, Merck has become a leading oncology company and achieved more than 140 medicine and vaccine approvals globally across numerous therapeutic areas.

Clinical Development 52

Clinical Development Development Vaccination Vaccine 52

The Pharma Data

SEPTEMBER 15, 2020

In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval. Internal Medicine. 20vPnC showed a safety and tolerability profile that was similar to Prevnar 13 ® Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]. and -50.4%

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98